News
ITCI
75.76
+2.92%
2.15
Intra-Cellular Therapies Price Target Raised to $95.00/Share From $92.00 by Morgan Stanley
Dow Jones · 1d ago
Intra-Cellular Therapies Is Maintained at Overweight by Morgan Stanley
Dow Jones · 1d ago
Morgan Stanley Maintains Overweight on Intra-Cellular Therapies, Raises Price Target to $95
Benzinga · 1d ago
Intra-Cellular price target raised to $95 from $92 at Morgan Stanley
TipRanks · 1d ago
Intra-Cellular Therapies (ITCI) Gets a Buy from Morgan Stanley
TipRanks · 1d ago
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
Barchart · 1d ago
Weekly Report: what happened at ITCI last week (0930-1004)?
Weekly Report · 5d ago
Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (12 Ratings)
Benzinga · 10/04 17:04
Intra-Cellular Therapies Is Maintained at Outperform by RBC Capital
Dow Jones · 10/04 15:05
Intra-Cellular Therapies Price Target Raised to $108.00/Share From $106.00 by RBC Capital
Dow Jones · 10/04 15:05
RBC Capital Maintains Outperform on Intra-Cellular Therapies, Raises Price Target to $108
Benzinga · 10/04 14:55
Weekly Report: what happened at ITCI last week (0923-0927)?
Weekly Report · 09/30 09:24
Jefferies Keeps Their Buy Rating on Intra-Cellular Therapies (ITCI)
TipRanks · 09/24 12:16
Weekly Report: what happened at ITCI last week (0916-0920)?
Weekly Report · 09/23 09:24
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
Barchart · 09/23 07:00
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business
Simply Wall St · 09/22 13:02
Intra-Cellular Therapies Price Target Maintained With a $130.00/Share by Cantor Fitzgerald
Dow Jones · 09/20 17:34
Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $130 Price Target
Benzinga · 09/20 17:24
Intra-Cellular Therapies Price Target Maintained With a $130.00/Share by Cantor Fitzgerald
Dow Jones · 09/16 16:00
Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $130 Price Target
Benzinga · 09/16 15:50
More
Webull provides a variety of real-time ITCI stock news. You can receive the latest news about Intra-Cellular Therapies through multiple platforms. This information may help you make smarter investment decisions.
About ITCI
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.